Clinical Trial Update: Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the safety, tolerability, and pharmacodynamics of RTA 402 in patients with liver disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• RTA 402 (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Liver Disease | Phase 1, Phase 2 | Status: TERMINATED